Assessment of CK2 constitutive activity in cancer cells

Maria Ruzzene1, Giovanni Di Maira, Kendra Tosoni

  • 1Department of Biological Chemistry, and VIMM (Venetian Institute of Molecular Medicine), University ofPadova, Padova, Italy.

Methods in Enzymology
|November 2, 2010
PubMed

Insights

Protein kinase CK2 (casein kinase 2) is constitutively active and elevated in cancer, driving malignancy. This study details methods to quantify CK2 activity for cancer diagnosis and therapeutic targeting.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein kinase CK2 (casein kinase 2) is constitutively active, unlike most kinases that require specific stimuli for activation.
  • Elevated CK2 levels in cancer cells promote malignancy through a mechanism termed 'non-oncogene addiction'.
  • CK2's constitutive activity and overexpression in cancer make it a potential therapeutic target and a prognostic marker for neoplastic transformation.

Purpose of the Study:

  • To describe reliable, sensitive, and specific methods for quantifying CK2 activity.
  • To provide experimental details for optimizing these assays, even in complex biological samples.
  • To enable the prognostic exploitation of CK2 levels and identify therapeutic strategies.

Main Methods:

  • In vitro quantification of CK2 activity in biological samples and cell lysates.
  • In-cell assays measuring endogenous CK2 activity via reporter substrate phosphorylation.
  • Identification of CK2 targets in both malignant and normal cells.

Main Results:

  • Established procedures for accurate CK2 activity measurement.
  • Optimized assays for high sensitivity and specificity in diverse biological contexts.
  • Methods applicable to clinical diagnostics and research.

Conclusions:

  • Accurate quantification of CK2 activity is crucial for its use as a prognostic marker and therapeutic target in cancer.
  • The described methods facilitate reliable assessment of CK2 levels in various biological samples and living cells.
  • This work supports the development of CK2-targeted cancer therapies and diagnostics.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...